Dianthus Therapeutics, Inc. · NASDAQ:DNTH
Dianthus Therapeutics — Magenta Therapeutics — Merger or Acquisition (August 2023)
22 slides from Dianthus Therapeutics's merger presentation, Aug 31, 2023
Slide 1: Corporate Presentation August 2023
Filed by Magenta Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Magenta Therapeutics, Inc. (Commission File No. 333-271917) Corporate Presentation Augus
Slide 2: Disclaimer: Forward Looking Statements
DISCLAIMER Forward Looking Statements Certain statements in this presentation (“Presentation”), other than purely historical information, may constitute “-florw ookard ing statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the Un
Slide 3: Disclaimer (continued)
DISCLAIMER (continued) No Offer or Solicitation This Presentation and the information contained herein is not intended to and shall not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the Proposed Transaction or (ii) an offer to buy or se
Slide 4: Advancing next-generation complement therapies for autoimmune disease patients
Advancing next-generation complement therapies to improve the lives of autoimmune disease patients Founded in 2019 to develop next-generation complement therapies to treat severe autoimmune diseases Lead program, DNTH103, is a potent investigational monoclonal antibody that targets the classical com
Slide 5: Accomplished team of biotech industry veterans and scientists
Accomplished team of biotech industry veterans and scientists committed to bringing innovation to market SENIOR MANAGEMENT BOARD OF DIRECTORS Lonnie Moulder Chairman of the Board, Dianthus Tomas Kiselak Marino Garcia Ryan Savitz Adam Veness, Esq. Simrat Randhawa, M.D. Managing Member, Fairmount Pres
Slide 6: Pipeline with best in class potential in multiple neuromuscular indications
DNTH103 offers pipeline in a product, best in class potential in multiple neuromuscular indications Program (Target) Target Population 2024 2025 Generalized Myasthenia Initiate Ph. 2 trial Q1’24 Top-line Ph. 2 data 2H’25 Gravis (gMG) ~60,000 U.S. patients DNTH103 Multifocal Motor (S.C. Active C1s Ne
Slide 7: Opportunity in Myasthenia Gravis
DNTH103 Opportunity in Myasthenia Gravis
Slide 8: gMG represents a multi billion-dollar opportunity with only two approved classes
gMG represents a multi billion-dollar opportunity with only two approved classes, each with room to improve Complement Class FcRn Class Soliris & Ultomiris U.S. gMG estimated Vyvgart sales >$5B in sales and in gMG showing rapid growth patient population: growing ~60,000 Approved in gMG, aHUS, Estima
Slide 9: Target product profile is highly differentiated vs. approved biologics for gMG
DNTH103 target product profile is highly differentiated vs. currently approved biologics for gMG Need for increased convenience and Lower volume, less frequent, self-administered S.C. reduced patient burden DNTH103 More frequent and/or higher-volume S.C.; must be administered by health care professi
Slide 10: Complement inhibitors are well established in gMG and other autoimmune disorders
Complement inhibitors are well established in gMG and other severe autoimmune disorders Targeting C1s preserves critical immune activity of lectin and alternative pathways, with the aim to provide a safer therapeutic option versus terminal pathway inhibitors Active form selectively inhibited by DNTH
Slide 11: C1s is a clinically validated target in the classical complement pathway
C1s is a clinically validated target in the classical complement pathway with an FDA approved therapy C1q 3 1 The C1 complex C1s is the only target of The initial component of the 1 the C1 complex with an 2 classical complement pathway FDA approved therapy consisting of C1q, C1r and C1s Enjaymo®, FD
Slide 12: DNTH103 exploits validated C1s biology with best-in-class properties
DNTH103 exploits validated C1s biology and has been designed with best-in-class properties High selectivity and potency Low volume S.C. delivery ▪ >10,000-fold binding affinity for ▪ Successful manufacturing of 150mg/mL Active C1s versus proC1s formulation ▪ Picomolar binding affinity▪ Low viscosity
Slide 13: Clinical Development
DNTH103 Clinical Development
Slide 14: Phase 1 healthy volunteer study design
DNTH103 Phase 1 healthy volunteer study was designed to validate extended half-life, potency and safety SAD Completed Cohorts Required to Initiate Ph. 2 Trials 36 HVs enrolled into five cohorts: • Placebo (N= up to 2) • Treated (N= up to 6) SAD MAD I.V. Administration S.C. Administration S.C. Admini
Slide 15: DNTH103 demonstrated deep and sustained complement inhibition in healthy volunteers
DNTH103 has demonstrated deep and sustained complement inhibition in healthy volunteers I.V. SAD: S.C. MAD: PK/PD: Half-life Extended PK (~60-days) Strong Accumulation with Q2W Dosing Analysis Demonstrates IC90 of 83 µg/mL 150 600 100 500 80 400 100 60 300 40 200 50 20 100 0 0 0 0 7 14 21 28 0 7 14
Slide 16: Phase 1 data confirms potent inhibition as a Q2W S.C. injection
DNTH103 Phase 1 data confirms potent inhibition of the classical pathway as a Q2W S.C. injection 200 300 Day 0: 15mg/kg I.V. Ph. 1 Data Confirms Starting Day 7: • ~60-day half-life 150 300mg S.C. Q2W • IC90 calculated at 83 µg/mL 100 IC90 – 83 µg/mL Dosing Modeled • 15mg/kg I.V. on Day 0 50 • 300mg
Slide 17: DNTH103 improves neurotransmission and muscle contraction in an AChR+ MG model
DNTH103 improves neurotransmission and muscle contraction in an AChR+ MG model Ravulizumab* (1 μM) DNTH103 (0.1 μM) DNTH103 (1 μM) n=3 n=3 n=3 0 • Serum from MG patients used in a validated in vitro 1,2,3 MG model -10 -14.8% • Assessed improvement in neurotransmission and muscle contraction of ravul
Slide 18: S.C. gMG Phase 2 trial design
DNTH103 S.C. gMG Phase 2 trial design A global, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and PK / PD of DNTH103 administered S.C following initial loading dose Preliminary Design • Design: 60 male and female subjects 12-Week S.C. Treatment ran
Slide 19: MMN and CIDP offer rationale for next DNTH103 indications
MMN and CIDP offer clear biological and commercial rationale for next DNTH103 indications Chronic Inflammatory Multifocal Motor Neuropathy (MMN) Demyelinating Polyneuropathy (CIDP) Neuromuscular indications with No approved targeted ~5,000 - 10,000 ~15,000 No approved targeted high unmet biologic th
Slide 20: Corporate
Corporate
Slide 21: Strategy to initiate multiple Phase 2 trials in 2024
Strategy to initiate multiple Phase 2 trials in 2024 ahead of transformative Phase 2 gMG readout Recent 2024 2025 Accomplishments Ph. 1 HV trial initiated in Initiate Top-line 2H Q1 gMG November 2022 Ph. 2 trial Ph. 2 data Successful manufacturing of Initiate 150mg/mL formulation 1H MMN Ph. 2 trial
Slide 22: Well capitalized into Q2'26 and supported by leading life science investors
Well capitalized into Q2’26 and supported by leading life science investors 1 ▪ ~$180M cash balance post-closing ; no debt ▪ Cash runway expected into Q2’26 ▪ Share composition – single share class: 2 ▪ ~243M post-closing basic shares outstanding (pre-reverse stock split) ▪ ~272M post-closing fully
Magenta Therapeutics — Merger or Acquisition (August 2023) on 6ix